Contrast (vision)

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Mercoledì, Marzo 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

United States Cancer Contrast Media (Gadolinium, Iodinated) Market Size, Share & Trends Analysis Report 2024-2030 - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Marzo 15, 2024
Health, Oncology, Diagnosis, Breast cancer, Gadolinium, Medicine, MRI, Growth, Prevalence, Agent handling, Patient, Public, Private sector, GE HealthCare, Google Images, Lung cancer, Investment, Smoking, Contrast (vision), Air pollution, USD, Government, Iodine, Medical imaging

The "U.S. Cancer Contrast Media Market Size, Share & Trends Analysis Report by Type (Gadolinium-based Contrast Media, Iodinated Contrast Media), Modality (Nuclear Imaging, CT scans), Application (Breast Cancer, Lung Cancer), and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Cancer Contrast Media Market Size, Share & Trends Analysis Report by Type (Gadolinium-based Contrast Media, Iodinated Contrast Media), Modality (Nuclear Imaging, CT scans), Application (Breast Cancer, Lung Cancer), and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. cancer contrast media market is anticipated to reach USD 1.53 billion by 2030 and is anticipated to expand at a CAGR of 11.7% from 2024 to 2030.
  • Thus, these factors collectively propel the growth of U.S. cancer contrast media market.
  • Iodinated contrast media dominated the type segment with a share of 39.5% in 2023 owing to the increasing medical imaging procedures.

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy

Retrieved on: 
Lunedì, Novembre 21, 2022
COVID-19, Nicorandil, LOS, Acute kidney injury, Kidney disease, Literature, Kidney, Health care, Liver disease, Safety, Therapy, Degenerative disease, Enzyme, Biotechnology, Patient, Contrast (vision), KATP, Liver, Disease, Randomized controlled trial, Patent, Security (finance), BID, AMD, MHRA, Mitochondrial disease, Geographic atrophy, GA, Failure, Severe cognitive impairment, Medication, Animal, Oxidative stress, Coronavirus, Hyperphosphatemia, FDA, Pharmaceutical industry, SUR2B

LOS ALTOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced key findings of UNI-494 efficacy from a preclinical study in animal models of Geographic Atrophy (GA).

Key Points: 
  • LOS ALTOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced key findings of UNI-494 efficacy from a preclinical study in animal models of Geographic Atrophy (GA).
  • The Company evaluated the effect of UNI-494 in preventing visual function loss in a rat model of GA.
  • The study evaluated four groups (n=8 per group): untreated, vehicle control, low dose of UNI-494, and high dose of UNI-494.
  • Further preclinical studies are planned to investigate these promising findings of the effect of UNI-494 in improving visual function.